Stocks · News reference
$15.0 Million Award to Support Advancement of RECLAIM-LN, a Phase 2 Potentially Registrational Trial of FT819 Off-the-Shelf CAR T-Cell Therapy in Lupus NephritisCLIN2 Grant is a highly competitive award from CIRM to
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-11-05 AccNo: 0001193125-26-449840 Size: 451 KB Item 1.01: Entry into a Material Definitive Agreement Item 1.02: Termination of a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits
Fate Therapeutics announced its financial results for the third quarter ended September 30, 2026, alongside updates on its clinical-stage autoimmune and oncology programs.
Fate Therapeutics, Inc. granted stock options and restricted stock units to newly hired non-executive employees as an inducement for employment.
Recent industry reporting highlights developments involving Artiva Biotherapeutics' NK cell therapy and Fate Therapeutics.
Fate Therapeutics shared updated preliminary clinical data for its FT819 cell therapy candidate during the American Society of Nephrology's Kidney Week 2026 conference.